Clinical indications for Pertuzumab

Pertuzumab (Pertuzumab) is a type of anti-tumor drug. It is sold under the trade name Perjeta after approval. Pertuzumab is indicated for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. Pertuzumab is indicated for use in combination with trastuzumab and chemotherapy; as part of a complete treatment regimen for early breast cancer, as a neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory or early-stage breast cancer (larger than 2 cm in diameter or lymph node positive), and as an adjuvant treatment for patients with HER2-positive early breast cancer with a high risk of recurrence.